Skip to content
Home
About Us
Leadership
Scientific Advisory Board
Board of Directors
Technology
Pipeline
Pipeline overview
Osteoporosis
Hypoparathyroidism
SBS & Obesity
Publications
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
Contact Us
Home
About Us
Leadership
Scientific Advisory Board
Board of Directors
Technology
Pipeline
Pipeline overview
Osteoporosis
Hypoparathyroidism
SBS & Obesity
Publications
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
Contact Us
SVB Securities Global Biopharma Conference
February 16, 2023
8:00 am
Publications
Click here for Webcast
READ MORE
March 4, 2026
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
Read More »
February 4, 2026
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
Read More »
December 22, 2025
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
Read More »
See all News
